Danaher (DHR) Benefits From Business Strength Amid Risks

Danaher Corporation (DHR) has been benefiting from strength in its Life Sciences segment driven by stable demand in the academic and life science research markets. Growth in demand for plasmids, proteins, gene writing and editing solutions augurs well for the segment.The company has been witnessing positive responses from its new products like IDBS' Polar Insight and Molecular Devices' CellXpress.ai, which help accelerate the drug discovery process and bring new therapies to market faster. Also, in the Diag ...